We have successfully synthesized (−)-epigallocatechin-3-gallate (EGCG) encapsulated nanostructured lipid carriers (NLCE) and chitosan coated NLCE (CSNLCE) using natural lipids, surfactant, chitosan and EGCG. Nanoencapsulation dramatically improved EGCG stability. CSNLCE significantly increased EGCG content in THP-1 derived macrophages compared with nonencapsulated EGCG. As compared to 10 M of nonencapsulated EGCG, both NLCE and CSNLCE at the same concentration significantly decreased macrophage cholesteryl ester content. NLCE and CSNLCE significantly decreased mRNA levels and protein secretion of monocyte chemoattractant protein-1 (MCP-1) levels in macrophages, respectively. These data suggest that nanoencapsulated EGCG may have a potential to inhibit atherosclerotic lesion development through decreasing macrophage cholesterol content and MCP-1 expression.
INTRODUCTION
Green tea is made from the dried leaves of the Camellia sinensis plant and has been considered a healthy beverage since ancient times. Different from fermented black tea and partially fermented oolong tea, green tea is produced from direct drying of fresh green tea leaves by hot steam and air. During this process, polyphenol oxidase is inactivated and catechins are preserved 1 . Green tea contains more catechins than black or oolong tea 2 . Catechins constitute about 14 to 33% of the dry green tea leaf weight 1, 3 . (−)-Epigallocatechin-3-gallate (EGCG) is the most abundant green tea catechin and comprises 25 to 55% of the total catechins 1, 3 . Over the past few decades many scientific and medical studies have already demonstrated many health benefits of green tea including antiatherogenic, anti-inflammatory and anti-tumorigenic properties 4 .
Cardiovascular disease (CVD) refers to the class of diseases that involve the heart and blood vessels. CVD is the leading cause of death in the United States and worldwide 5, 6 . About half of the CVD death is caused by atherosclerosis, which is a progressive disease characterized by lipid plaque formation in arteries, resulting in insufficient blood supply to heart muscle, brain or peripheral tissues (for example legs). Increased lipid accumulation and inflammatory responses are the major causes of atherosclerosis 7, 8 . Monocyte chemoattractant protein 1 (MCP-1) promotes the recruitment of monocytes into the aortic intima layer 7 . Upon the migration, monocytes are differentiated into macrophages in response to macrophage colony-stimulating factor. These macrophages express scavenger receptors, which increase the uptake of minimally modified low density lipoprotein (LDL), especially minimally oxidized LDL (oxLDL) 9 . After macrophages accumulate cholesterol, they are transformed into foam cells. Foam cells can secrete many inflammatory factors including MCP-1, which further recruit more monocytes, resulting in increased number of macrophages and later foam cells in the artery wall. After foam cells die, lipids (primarily cholesterol) are accumulated on the artery wall and atherosclerotic plaque is formed. Total cholesterol (TC) in macrophages includes cholesteryl ester (CE), a storage form of cholesterol, and free cholesterol (FC), which can be transported out of macrophages via a process termed reverse cholesterol transport. Foam cells formation and cholesterol accumulation in the vessel intima characterize the atherosclerotic lesion 9 . Therefore, macrophages play an important role in atherosclerotic lesion progression by facilitating cholesterol accumulation and increasing inflammatory responses in aortic walls.
EGCG has a potential to decrease the release of inflammatory factors and reduce cholesterol accumulation in macrophages [10] [11] [12] [13] , which may in turn prevent atherosclerotic lesion development. When apolipoprotein E null mice are treated with daily intraperitoneal injections of EGCG at a dose of 10 mg/kg body weight, cuff-induced evolving atherosclerotic lesion size is reduced by 55% after 21 days treatment 14 . Human studies indicate that EGCG can maintain cardiovascular health, but the evidence is inconclusive regarding the effectiveness for CVD prevention or treatment 15, 16 . The major problems are its low stability and bioavailability in humans or research animals [17] [18] [19] . The oral bioavailability of EGCG after drinking tea containing catechins at 10 mg/kg body weight is about 0.1% in humans and research animals 18, 20 . The peak plasma EGCG concentration is 0.15 M after drinking 2 cups of green tea 19 . Moreover, EGCG is unstable in water and physiological fluid in vitro 21 . EGCG stability is lowered by various metabolic transformations including methylation, glucuronidation, sulfation and oxidative degradation 22, 23 . Hence, there is a critical need to use biocompatible and biodegradable carriers to increase EGCG stability and uptake.
Nanotechnology involves the control of matter, generally in the range of 100 nm or smaller 24 . Nanocarriers may increase bioavailability of encapsulated EGCG, enhance its stability, lower its toxicity through preventing EGCG from prematurely interacting with the biological environment and improve intracellular penetration. Even though nanoparticles have many beneficial effects, they also have many disadvantages including expensive cost, complex synthesis procedures and potential side-effects. We successfully produced biocompatible and biodegradable EGCG encapsulated nanostructured lipid carriers (NLCE), which are composed of natural lipids, surfactant, EGCG and water. Nanostructured lipid carriers (NLCs) have received considerable attention because of their small size, stability, biocompatibility and biodegradability, low cytotoxicity, and easily scaled-up synthesis processes 25 . The NLC structure is composed of a hydrophilic shell and a hydrophobic lipid core, which is solid at room temperature. Chitosan, a natural polysaccharide, is an absorption enhancer 26, 27 . We have synthesized chitosan-coated NLCE (CSNLCE). Our hypothesis is that NLCs and CSNLCs can increase EGCG stability, increase EGCG uptake by THP-1 derived macrophages, and decrease cellular CE content and lower expression and secretion of inflammatory factors in those macrophages. coli lipopolysaccharide were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO).
Kolliphor HS15 was given as gift from BASF Chemical Co., USA (Florham Park, NJ). Soy lecithin (>95%) and 7-nitro-2-1, 3-benzoxadiazol-4-yl-phosphotidylcholine (NBD-PC) were purchased from Avanti Polar Lipids (Alabaster, AL). Trizol reagent, SuperScript™ III reverses transcriptase and power SYBR green master mix were purchased from Life Technologies Co. (Carlsbad, CA).
Preparation of NLCE and CSNLCE
NLC was prepared from a lipid mixture composed of the following lipids in wt%: 9.3% soy lecithin, 40.0% glyceryl tridecanoate, 6.7% glyceryl tripalmitate, 44.0% Kolliphor HS15 (polyoxyethylated 12-hydroxystearic acid, a non-ionic surfactant), and an aqueous mixture containing 2.6% EGCG and 1% of NaCl in deionized water. A novel phase inversion-based process was used in preparing NLCE 28 . Briefly, oil and aqueous phase were heated to 85°C and mixed together. Then, the mixture was treated with three temperature cycles from 60 to 85°C and from 85 to 60°C at a rate of 4°C per min and stirred at 375 rpm per min on a magnetic stirrer. In the last cycle, when the mixture was cooled to 70°C, cold deionized water (0°C) was added to the mixture. The volume ratio of cold water to lipid was 35:1 in this study. The fast cooling-dilution process resulted in NLCE formation. Afterward, a slow magnetic stirring was applied to the suspension for 45 min. Void nanostructured lipid carriers (VNLC) were synthesized by using the same method without adding EGCG. All steps in the preparation of VNLC and NLCE were performed under nitrogen to prevent EGCG and lipid degradation. NLCE and VNLC were concentrated and coated with 6 mg/ mL chitosan using a magnetic stirrer for 40 min at 4°C to form CSNLCE and chitosancoated VNLC (VCSNLC), respectively. The final concentration of chitosan in CSNLCE and VCSNLC was 2 mg/mL.
Encapsulation efficiency and loading capacity determination
The total EGCG concentration (C total ) in the nanocarrier solution was measured using a high performance liquid chromatography (HPLC) system (Waters Co., Milford, MA) with a C18 reverse-phase column (150 mm×4.6 mm, 5 m size) and Waters 2489 UV/Visible detector. The mixture of water/acetonitrile/ethyl acetate/sulfuric acid (86:12:2:0.043, v:v:v:v) was used as a mobile phase with flow rate of 1 mL/min. The detection wavelength was selected as 254 nm. Free EGCG was separated from nanoencapsulated EGCG using an ultrafiltration method (Millipore Amicon Ultra-15) at 10,000 × g at 4°C for 20 min, and measured by the HPLC system (C free ). In order to calculate the loading capacity, a certain volume of NLCE (V) was dried using a vacuum freeze-drying system (FreeZone 4.5 plus, Labconco, Kansas City, MO). The weight of dried NLCE was expressed as W NPS . Dried NLCE was only used for measuring loading capacity. Nanoparticle suspension was used for the rest experiments. The encapsulation efficiency and loading capacity of EGCG in the nanocarriers were calculated according to the following equations, respectively:
Particle size, zeta potential and morphology of nanocarriers The mean particle size was measured by dynamic light scattering (DLS), polydispersity index (PI) and zeta potential of nanocarriers were measured using a ZetaPALS analyzer (Brookhaven Corporation, Holtsville, NY). The morphology of the NLCE and CSNLCE was examined using a transmission electron microscope (TEM) instrument (200Kv Hitachi H-8100, Tokyo, Japan).
Stability study of NLCE, CSNLCE and nonencapsulated EGCG
The stability of NLCE, CSNLCE and nonencapsulated EGCG were determined in 1 X phosphate buffered saline (1 X PBS) at pH=1.0 3.0, 5.0, 7.4. Hydrochloric acid was used to adjust pH. The final concentration of nanoencapsulated and nonencapsulated EGCG was 100 M. The solutions were stored in tightly closed vials and incubated at 37°C. EGCG concentrations were measured after incubation for 0, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0 and 3.0 hours. To determine the EGCG stability at different temperatures, 100 M of nonencapsulated EGCG and nanoencapsulated EGCG (NLCE and CSNLCE) dissolved in 1XPBS (pH 7.4, ionic strength 157.5 mM) was incubated at 4°C for 14 days, 22°C for 19 hours and 37°C for 3 hours. We also measured their stability in RPMI1640 cell culture medium at 37°C with or without cells, and with or without superoxide dismutases (SOD, 5U/mL).
In vitro release study
The in vitro release behavior of nonencapsulated EGCG and NLCE were measured in 1 X PBS (pH 5.0) using a dialysis method. Samples of 1.0 mg of nonencapsulated EGCG and equivalent amount in NLCE were dissolved in 2 mL of 1 X PBS (pH 5.0) and then placed in the dialysis bags with MWCO 6,000-8,000. The dialysis bags were dipped in a conical flask containing 25 mL of 1 X PBS (pH 5.0) (dissolution medium) at 37°C and stirred at 250 rpm/ min. The dissolution medium was totally replaced by fresh pre-warmed medium every two hours in order to minimize the effect of EGCG degradation. The EGCG released into the medium was determined every 30 min using the HPLC system.
Cytotoxicity analysis
Human monocytic THP-1 cell line was purchased from the American Type Tissue Culture Collection (ATCC, Manassas, VA) and cultured in the RPMI1640 medium following to ATCC instructions. THP-1 cells (3 × 10 4 /well) in a 96-well plate were differentiated into macrophages by incubating with 50 ng/mL PMA for 72 hours. The THP-1 derived macrophages were treated with 1 X PBS, nonencapsulated EGCG, VNLC, NLCE, VCSNLC, CSNLCE dissolved in 1 X PBS (pH 7.4) for 18 hours. Three EGCG concentrations (5 M, 10 M and 20 M) were tested. The cell viability was measured using a 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay as previously described 29 . Three independent experiments were conducted with six replicates within one experiment.
The binding and uptake of fluorescent dye-labeled nanocarriers
We used the above phase inversion-based process to synthesize NBD-PC-labeled VNLC (NBD-VNLC) by replacing 1.0 mol% of total lipids with NBD-PC, and coated them with chitosan to form NBD-PC-labeled VCSNLC (NBD-VCSNLC). After incubating THP-1 derived macrophages with NBD-VNLC or NBD-VCSNLC, or 1 X PBS (pH 7.4) used as control at 4°C and 37°C, cellular binding and uptake of NBD-VNLC and NBD-VCSNLC were observed under a fluorescence microscopy (Olympus, USA) as previously described 29 . Microscopy settings were identical for all measures to allow equal comparison of the images. Fluorescence intensities were quantified using the NIH imageJ software.
Cellular EGCG content
THP-1 derived macrophages were incubated with 100 M of nonencapsulated EGCG and nanoencapsulated EGCG (NLCE and CSNLCE) in RPMI1640 medium with or without SOD (5U/mL) for 2 and 4 hours at 4°C or 37°C. After washing cells, the cellular EGCG was extracted and determined as previously described 29 . Total cellular protein levels were determined by using a bicinchoninic acid (BCA) kit (Pierce, Rockford, IL). Cellular EGCG content was expressed as g of EGCG per mg of protein.
Minimally oxidized LDL preparation and cellular cholesterol content measurement
LDL was isolated from human plasma by a sequential ultracentrifugation method 30 . Minimally oxidized LDL (oxLDL) was prepared by an adaptation of a previously described method 30 . THP-1 derived macrophages of 1.5 × 10 6 /well in 6-well plates were incubated with or without 40 mg protein/mL of minimally oxLDL in combination with the following treatments: 1XPBS, nonencapsulated EGCG, VNLC, NLCE, VCSNLC and CSNLCE containing 10 M of EGCG for 18 hours. After cellular lipid extraction using a chloroform and methanol mixture (2:1, v/v), FC and TC were measured using a HPLC system as previously described 30 . Stigmasterol was used as internal standard. Delipidated cellular protein levels were determined using a BCA kit. CE was calculated as the difference between TC and FC and expressed as mol of cholesterol per gram of protein.
Secretion of inflammatory factors
THP-1 derived macrophages were pretreated with 10 M of VNLC, VCSNLC, NLCE, CSNLCE, EGCG and 1 X PBS for 2 hours. Then, 50 ng/mL of Escherichia coli lipopolysaccharide (Sigma, St Louis, MO) was added into each well and incubated for additional 16 hours. Tumor necrosis factor alpha (TNF ), interleukin-6 (IL-6) and MCP-1 protein concentrations in the culture medium were determined using DuoSet ELISA kits (R&D Systems, Minneapolis, MN) as previously described 30 .
Real-time polymerase chain reaction
RNA was extracted from THP-1 derived macrophages using a Trizol reagent. cDNA was synthesized from RNA using SuperScript™ III reverse transcriptase according to the manufacturer's instructions. MCP-1 and TNF primers were designed and tested in our previous publication 30 . Beta-actin was used as an endogenous control. cDNA levels of MCP-1 and TNF were measured using power SYBR green master mix on a Real-time PCR system (Eppendorf, Hauppauge, NY). mRNA-fold change was calculated using the 2(-Delta Delta C(T)) method 30 .
Statistical analysis
Data analysis was conducted using Statistical Package for the Social Sciences (SPSS). Oneway ANOVA followed by Tukey HSD Post Hoc test was performed to compare multiple group means. Independent student's t-test was performed to compare two group means. Differences were considered statistically significant at p<0.05. Data in figures and tables are expressed as means ± standard deviation (SD).
Safety information
The MTT dye reagent is hazardous; avoid contact with skin and eyes. MTT solvent is flammable and corrosive. Wear lab coat, gloves and safety glasses when working with this reagent.
RESULTS AND DISSCUSSION

Characteristics of nanocarriers
EGCG is a promising natural compound for atherosclerosis prevention and treatment. However, its low levels of stability and cellular bioavailability limit its anti-atherogenic (Table 1) . PI values were relatively low (<0.3), which indicates a high level of uniformity (Table 1) . Studies have shown that nanocarriers smaller than 100 nm are cleared much slower than large carriers by the reticulo-endothelial system in the liver and spleen 24, 34 . VNLC and NLCE were negative charged. After coating them with chitosan, VCSNLC and CSNLCE became slightly larger and positively charged (Table 1) . Chitosan is a natural and biocompatible polysaccharide obtained by deacetylation of chitin from exoskeleton of crustaceans like crabs and shrimps, which can enhance the stability and bioavailability of nanocarriers and nanoencasulated compounds 35 . Table 1 also showed the changes of particle size, PI and zeta potential of NLCE and CSNLCE in deionized water at 4°C and 37°C. After 4°C storage for 50 days, the size, PI and zeta potential of VNLC, NLCE and VCSNLC were slightly changed, but the size and PI of CSNLCE were increased more than 1.3 fold. Surface charge is important in nanocarrier systems. In general, higher absolute surface charge leads to stronger repulsion interactions among nanocarriers, and hence higher stability. After incubation at 37°C for 24 hours, the size and PI of nanocarriers did not change dramatically, but the absolute zeta potential values were decreased. In this study, mixing glyceryl tridecanoate and glyceryl tripalmitate can form less perfect crystals in the lipid core, which can accommodate more EGCG. The encapsulation efficiency is about 99% and loading capacity is around 3%. Glyceryl tridecanoate is solid at room temperature and liquid in body temperature, which can improve EGCG storage stability in vitro and bioactivity in vivo. Both NLCE and CSNLCE were spherical under a transmission electron microscope (TEM) (Figure 1A and 1B) . The average size of NLCE and CSNLCE measured using TEM was consistent to the dynamic light scattering measures. Many studies indicated that the nature and amounts of surfactants and lipids determine the characteristics of nanocarriers, such as particle size and encapsulation efficiency 33, 36 . Higher lipid amounts (larger hydrophobic core) can accommodate more EGCG, but form large nanocarriers 37 . The particle size of nanocarriers was dependent on the ratio of lipids to surfactants. In consistent to other studies 33, 36 , we found that as the ratio of triglycerides to Kolliphor HS15 was decreased, the size of nanocarriers was decreased (data not shown). Based on these preliminary data, we chose 1:1 ratio of triglycerides to Kolliphor HS15, which gave small size (48 nm in diameter) and high encapsulation efficiency (about 99%).
The chemical stability of NLCE, CSNLCE and nonencapsulated EGCG
We measured the chemical stability of 100 M of nonencapsulated and nanoencapsulated EGCG in different temperatures and pH values. NLCE, CSNLCE and nonencapsulated EGCG were stable in the acidic pH ranging from 1.0 to 5.0 at 37°C for 3 hours (data not shown). EGCG is unstable under alkaline or neutral conditions 38 . In the neutral pH 7.4, nanoencapsulation significantly increased the percentage of EGCG remaining at three tested temperatures (4°C, 25°C and 37°C) (Figure 2 ). At 4°C, 100% of nonencapsulated EGCG was degraded after 1 day, whereas the degradation rate of EGCG in NLCE and CSNLCE was less than 5%. After 14 days, 75% and 25% of EGCG were remained in CSNLCE and NLCE at 4°C (Figure 2A) . After incubating them for 8 hours at 22°C, the percentage of remained EGCG in nonencapsulated EGCG, NLCE and CSNLCE was 1.5%, 55% and 89%, respectively ( Figure 2B ). At 37°C, nonencapsulated EGCG were completely degraded after 3 hours, however, the percentage of remained EGCG in NLCE and CSNLCE was 33% and 64%, respectively ( Figure 2C ). In addition, concentrated nanoencapsulated EGCG can be stored at 4°C for a long period of time without obvious degradation. After storing NLCE and CSNLCE in neutral 1 X PBS containing 3000 M of nanoencapsulated EGCG at 4°C for 50 days, we still detected 82% and 92% of EGCG in NLCE and CSNLCE, respectively. These results indicated that nanoencapsulation significantly increased EGCG stability. NLC has a solid lipid core at room temperature. Amphiphilic and pH sensitive compounds can be easily encapsulated into the lipid core and are stable in the solid lipid core 39 . Recently, many studies indicated that green tea catechins may undergo degradation, oxidation, epimerization and polymerization, which could be contributed by many factors such as temperature, pH of the system, oxygen levels and the presence of metal ions 3, 40 . Nanoencapsulation increases EGCG stability through preventing EGCG from prematurely interacting with the biological environment 33, 35, 41 .
Nanoencapsulation also enhances EGCG stability in RPMI1640 medium at 37°C. After incubating 100 M of nonencapsulated and nanoencapsulated EGCG in RPMI1640 medium without THP-1 derived macrophages for 1 hour, the percentage of remained EGCG in nonencapsulated EGCG, NLCE and CSNLCE was 3.7%, 27% and 31%, respectively ( Figure 3A) . As compared to 1 X PBS, RPMI1640 medium decreased the stability of nonencapsulated and nanoencapsulated EGCG ( Figure 2C and 3A) , which is consistent with EGCG stability order in another study: water > 1XPBS > culture medium 42 . The presence of metal ions and proteins in cell culture might contribute to decreased EGCG stability 21 . SOD dramatically increased nonencapsulated EGCG stability in RPMI1640 medium ( Figure 3B) . Therefore, the stability of NLCE, CSNLCE and nonencapsulated EGCG was similar in the presence of SOD at 37°C (Figure 3B ). In the neutral 1 X PBS and medium, EGCG is easily auto-oxidized, forming EGCG dimmers. After adding SOD into the incubation medium, auto-oxidation and dimmer formation were inhibited 21, 42 .
We measured EGCG concentrations in RPMI1640 medium in the presence of THP-1 derived macrophages, which were treated with 100 M of NLCE, CSNLCE and nonencapsulated EGCG at 4°C and 37°C. Even though macrophages took up nonencapsulated and nanoencapsulated EGCG from medium, the EGCG concentrations in the medium were higher in the presence of macrophages compared to in the absence of cells at 37°C ( Figure 3A-B and 4C-D) . The concentrations of nanoencapsulated and nonencapsulated EGCG in culture medium were higher at 4°C compared to 37°C ( Figure  4) . SOD increased the concentrations of nanoencapsulated and nonencapsulated EGCG in culture medium at 4°C and 37°C ( Figure 4B and Figure 4D ). Hong J. et al. demonstrated that adding 50 M of EGCG to cell culture medium increased H 2 O 2 production, which can decrease EGCG stability 21 . However, the amount of H 2 O 2 was decreased in the presence of cells 21 . Other studies indicated that increased H 2 O 2 production by EGCG instead of direct effects of EGCG resulted in cancer cell growth inhibition and apoptosis in vitro 43, 44 . Cells in the culture medium can produce glutathione peroxidase and catalase, which can decompose H 2 O 2 and further improve EGCG stability 43, 44 . Based on these data, SOD (5U/ mL) was used to stabilize EGCG for measuring the uptake of nonencapsulated and nanoencapsulated EGCG by macrophages 42 .
Cellular binding and uptake of NBD-nanocarriers
The binding and uptake of NBD-labeled nanocarriers in THP-1 derived macrophages were observed under a fluorescence microscope after treating macrophages with NBD-VNLC ( Figure 5A ) and NBD-VCSNLC ( Figure 5B) for 2, 4, 6, 18 and 24 hours at 37°C and 4 hours at 4°C. The green and blue colors denote NBD-nanocarriers and cell nuclei, respectively. More NBD-nanocarriers were bound and taken up by macrophages at 37°C compared to 4°C. As incubation time was increased, the binding and uptake of NBD-VNLC and NBD-VCSNLC in macrophages were gradually increased and reached the peak at hour 18. After incubation for 24 hours, the binding and uptake of NBD-VNLC and NBD-VCSNLC in macrophages were decreased ( Figure 5C ). Nanocarriers degradation caused by enzymes or environmental factors may partially contribute to the decreased uptake after long-term incubation. As compared to NBD-VNLC, more NBD-VCSNLC was taken up and bound to macrophages (Figure 5A-C) . The data further confirm chitosan is an uptake enhancer. According to fluorescence imaging data, the binding and uptake of NBD-VNLC and NBD-VCSNLC in macrophages were temperature-and time-dependent ( Figure 5C ).
Macrophage EGCG content
To measure the cellular EGCG content, THP-1 derived macrophages were incubated with 100 M of nonencapsulated EGCG, NLCE and CSNLCE at 4°C or 37°C for 2 and 4 hours. After incubation at 37°C for 2 hours in the absence of SOD, the EGCG content in macrophages treated by nonencapsulated EGCG, NLCE and CSNLCE was 0.031, 0.096, 0.14 g/mg protein, respectively (data not shown). In the presence of SOD, the EGCG content was increased to 0.098, 0.176, 0.307 g/mg protein in macrophages treated by nonencapsulated EGCG, NLCE and CSNLCE at 37°C for 2 hours, respectively ( Figure 6 ). After incubation at 37°C for 4 hours in the presence of SOD, the EGCG content in macrophages treated by nonencapsulated EGCG, NLCE and CSNLCE was 0.109, 0.458, 0.853 g/mg protein, respectively (Figure 6 ). SOD significantly increased cellular EGCG content among all treatments, which might be partially due to its function in enhancing EGCG stability. No matter in the absence or presence of SOD, nanoencapsulated EGCG, especially CSNLCE, dramatically increased macrophage EGCG content compared to nonencapsulated EGCG (Figure 6 ). Increased macrophage EGCG content by NLCE and CSNLCE could be partially caused by enhanced EGCG stability. Except nonencapsulated EGCG, 4-hour incubation resulted in higher macrophage EGCG content than 2-hour incubation at both 4°C and 37°C (Figure 6 ). In consistent with other study 21 , macrophages incubated with 100 M of nonencapsulated EGCG or NLCE at 4°C had higher EGCG content than those incubated at 37°C (Figure 6 ). The high stability of nonencapsulated EGCG and NLCE at 4°C may partially contribute to the results. Another reason might be an increase in EGCG efflux from macrophages at 37°C. Nonencapsulated EGCG at a concentration range from 5 to 640 M is taken up by cells through passive diffusion process and subsequently converted to the methylated metabolites and glucuronides, which together with nonencapsulated EGCG may be pumped out by cells through multi-drug-resistance proteins or P-glycoproteins 21, 45 . This efflux rate was higher at 37°C than it at 4°C. This energy-dependent efflux process may further explain why cellular EGCG content was higher at 4°C than it at 37°C.
In vitro release study
The release behavior of nonencapsulated EGCG and NLCE was investigated using a dialysis method. Dynamic dialysis was chosen for separation of free EGCG from NLCE. In Figure  7 , nonencapsulated EGCG exhibited a much faster dissolution rate with 100% released within the initial 2-hour period. In contrast, only 2% of EGCG was released from NLCE within the first 2 hours. After 9 hours, only 4.43% of EGCG was released from NLCE ( Figure 7) . The data indicated that increased cellular EGCG content by NLCE was due to uptake of nanocarriers, not nonencapsulated EGCG released from nanocarriers. We confirmed this result with the ultrafiltration method (Millipore Amicon Ultra-15). More Zhang et al. Page 8 studies are required to investigate the membrane receptors in transporting NLCE and CSNLCE, organelles and enzymes for metabolizing them.
Cytotoxicity study
After treating THP-1 macrophages with 5, 10, and 20 M of nonencapsulated or nanoencapsulated EGCG (NLCE and CSNLCE) and responsive void nanocarriers (VNLC and VCSNLC) for 18 hours, the cell viability was more than 90% among all treatments (Figure 8) . The data indicate the NLCE and CSNLCE and their void nanocarriers had a very low level of toxicity in the tested concentration range.
Macrophage cholesterol accumulation
In the absence or presence of minimally oxLDL in the culture medium, nanoencapsulated EGCG significantly decreased macrophage CE content as compared to 1 X PBS, nonencapsulated EGCG and void nanocarriers. In the absence of oxLDL, CSNLCE and NLCE resulted in 9.4-fold and 2.7-fold lower macrophage CE content than nonencapsulated EGCG, respectively ( Figure 9A ). In the presence of minimally oxLDL, CSNLCE and NLCE resulted in 5.2-fold and 2.9-fold lower macrophage CE content than nonencapsulated EGCG, respectively ( Figure 9B ). Even though NLCE and CSNLCE decreased macrophage TC content, but they did not reach a statistical difference due to high standard deviations.
The rate-limiting enzyme in cholesterol biosynthesis is 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) 10 . Nonencapsulated EGCG at 50 M or higher concentrations can decrease de novo cholesterol synthesis through decreasing HMGCR expression and activity 10, 46 . Miura Y et al. fed male apolipoprotein E null mice with an atherogenic diet (high fat and cholesterol) in combination with a green tea extract drink (0.8 g/L), or a vehicle drink 47 . The green tea extract drink decreased the atheromatous area and aortic cholesterol content by 23% and 27%, respectively 47 . In the current study, NLCE and CSNLCE containing 10 M of EGCG significantly decreased macrophage CE content, but nonencapsulated EGCG at the same concentration had no effect on lowering macrophage cholesterol content. The data indicate that nanoencapsulated EGCG retains its bioactivities and exhibits high efficacy at low dose.
Expression and secretion of inflammatory factors
As compared to nonencapsulated EGCG, NLCE significantly decreased mRNA levels of MCP-1 ( Figure 10A) , and CSNLCE significantly decreased MCP-1 release from macrophages ( Figure 10B ). The release of TNF and IL-6 from macrophages and mRNA levels of TNF was similar among all treatments (data not shown). MCP-1 promotes the recruitment of monocytes into the aortic intima layer and atherosclerotic lesion development 7 . Human studies have shown that elevated plasma MCP-1 concentrations can serve as a direct marker of atherosclerosis 7, 48 . EGCG decreased mRNA and protein levels of MCP-1 in human endothelial cells in a dose-dependent manner (5-30 M) through inhibiting p38 mitogen-activated protein kinases (MAPK) and nuclear factor-kappaB (NFkB) activation 11 . After treating monocytes or macrophages with 100 M of EGCG, MCP-1 expression and secretion, and THP-1 migration were inhibited via inhibiting NF-kB activation 12, 13 . When rodents were fed with a diet containing EGCG, blood MCP-1 concentrations were decreased 49, 50 .
In summary, NLCE and CSNLCE significantly enhanced EGCG stability, improved its sustained release, increased its cellular bioavailability, decreased cholesterol content and MCP-1 expression in macrophages, which have a potential for preventing and reversing atherosclerotic lesion development. Stability of 100 M of nonencapsulated EGCG, NLCE and CSNLCE in RPMI1640 medium at 37°C in the absence of SOD (A); or in the presence of 5U/mL of SOD (B). Means at a time point without a common superscript differ, P < 0.05. Macrophage EGCG content. THP-1 derived macrophages were treated with 100 M of nonencapsulated EGCG, NLCE, and CSNLCE in RPMI1640 medium containing SOD (5U/ mL) for 2 and 4 hours at 4°C or 37°C. Three independent experiments were conducted. Compared to nonencapsulated EGCG, CSNLCE increased EGCG content *, P < 0.05; **, p< P < 0.01; compared to NLCE, CSNLCE increased EGCG content #, P < 0.05. In vitro EGCG release profiles of nonencapsulated EGCG and NLCE. Three independent experiments were conducted. Macrophage cholesterol content. THP-1 derived macrophages were treated with 10 M of VNLC, VCSNLC, NLCE, CSNLCE, EGCG and 1 X PBS for 18 hours in the absence of minimally oxLDL (A), three independent experiments were conducted; and in the presence of oxLDL (B), six independent experiments were conducted. Compared to 1 X PBS, EGCG, VNLC and VCSNLC, NLCE and CSNLCE decreased macrophage CE content *, P < 0.05; **, P < 0.01. MCP-1 mRNA levels (A) and protein secretion (B) in/from THP-1 derived macrophages treated with 10 M of VNLC, VCSNLC, NLCE, CSNLCE, EGCG and 1 X PBS for 18 hours. Three independent experiments were conducted. Bars without a common superscript differ, P < 0.05. 
